SCE dermatology

SCE dermatology updated dermatological information is continuously posted in this page.

12/04/2026

Pulpitis refers to skin lesions involving the digital pulps or fingertips, often accompanied by symptoms such as stingin...
12/04/2026

Pulpitis refers to skin lesions involving the digital pulps or fingertips, often accompanied by symptoms such as stinging, burning, tingling and bleeding . Itch may be present, with varying intensity. This clinical presentation may result from different conditions, including ICD, ACD, PCD, atopic dermatitis and psoriasis . A pincer grasp pattern may guide clinical suspicion towards ACD, PCD or even ICD . Typically, pulpitis presents as well-demarcated eczematous lesions, with erythema and desquamation, on the fingertips, extending from the distal crease to ventral aspects of the fingertips. These areas are frequently associated with fissures. In some cases, the lesions may spread from the tips to the entire fingers or even the palms.

12/04/2026
12/04/2026

Dx?

12/04/2026

A 68-year-old woman with rosacea presented with a 6-week history of dark patches on the skin of her arms and legs. Two weeks before the onset of the skin changes, she had started taking minocycline daily.

Dx?Name the sign?
26/03/2026

Dx?
Name the sign?

A 68 y/o man with interstitial lung disease and skin changes characterized by alternating areas of hypopigmentation and hyperpigmentation on sclerotic skin.

? What is the most likely diagnosis ?

I've just reached 6K followers! Thank you for continuing support. I could never have made it without each and every one ...
26/03/2026

I've just reached 6K followers! Thank you for continuing support. I could never have made it without each and every one of you. 🙏🤗🎉

23/03/2026
Icotyde™ (icotrokinra), the first targeted oral IL-23 receptor antagonist, is now FDA-approved for moderate-to-severe pl...
22/03/2026

Icotyde™ (icotrokinra), the first targeted oral IL-23 receptor antagonist, is now FDA-approved for moderate-to-severe plaque psoriasis in adults and adolescents 12+. With strong Phase 3 data and up to 55% PASI 90 at Week 16, this once-daily option could shift how we think about systemic therapy

Icotyde™ (icotrokinra), the first targeted oral IL-23 receptor antagonist, is now FDA-approved for moderate-to-severe plaque psoriasis in adults and adolescents 12+. With strong Phase 3 data and up to 55% PASI 90 at Week 16, this once-daily option could shift how we think about systemic therapy.

Congratulations to Johnson & Johnson on this milestone.

Read more on the DEF blog 🔗 in story

Address

London
London
SW1A2

Website

Alerts

Be the first to know and let us send you an email when SCE dermatology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category